JP2011515458A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515458A5
JP2011515458A5 JP2011501337A JP2011501337A JP2011515458A5 JP 2011515458 A5 JP2011515458 A5 JP 2011515458A5 JP 2011501337 A JP2011501337 A JP 2011501337A JP 2011501337 A JP2011501337 A JP 2011501337A JP 2011515458 A5 JP2011515458 A5 JP 2011515458A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral pharmaceutical
protease inhibitor
composition according
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011501337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515458A (ja
JP5395160B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2009/000223 external-priority patent/WO2009118722A2/en
Publication of JP2011515458A publication Critical patent/JP2011515458A/ja
Publication of JP2011515458A5 publication Critical patent/JP2011515458A5/ja
Application granted granted Critical
Publication of JP5395160B2 publication Critical patent/JP5395160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011501337A 2008-03-26 2009-02-26 タンパク質の経口投与方法及び組成物 Active JP5395160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6477908P 2008-03-26 2008-03-26
US61/064,779 2008-03-26
PCT/IL2009/000223 WO2009118722A2 (en) 2008-03-26 2009-02-26 Methods and compositions for oral administration of proteins

Publications (3)

Publication Number Publication Date
JP2011515458A JP2011515458A (ja) 2011-05-19
JP2011515458A5 true JP2011515458A5 (enExample) 2012-04-05
JP5395160B2 JP5395160B2 (ja) 2014-01-22

Family

ID=41114402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011501337A Active JP5395160B2 (ja) 2008-03-26 2009-02-26 タンパク質の経口投与方法及び組成物

Country Status (10)

Country Link
US (3) US10058593B2 (enExample)
EP (2) EP2279244B1 (enExample)
JP (1) JP5395160B2 (enExample)
CN (1) CN102037121B (enExample)
AU (1) AU2009230718B2 (enExample)
CA (3) CA3083198A1 (enExample)
NZ (1) NZ588603A (enExample)
RU (1) RU2504373C2 (enExample)
WO (1) WO2009118722A2 (enExample)
ZA (1) ZA201007522B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006288703B2 (en) * 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
CA3083198A1 (en) 2008-03-26 2009-10-01 Oramed Ltd. Methods and compositions for oral administration of proteins
EP2300031B1 (en) * 2008-05-05 2017-09-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
ES2561652T3 (es) 2010-02-25 2016-02-29 Evonik Röhm Gmbh Formulación farmacéutica o nutracéutica
NZ604805A (en) 2010-07-09 2014-09-26 Affibody Ab Polypeptides
ES2644962T3 (es) * 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (en) * 2012-02-01 2024-04-10 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
US20160009767A9 (en) * 2012-03-28 2016-01-14 Affibody Ab Oral administration
US10155792B2 (en) 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
EP2941267B1 (en) * 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
WO2014191545A1 (en) * 2013-05-30 2014-12-04 Novo Nordisk A/S Novel oral pharmaceutical composition for treatment of diabetes
EP3083675B1 (en) 2013-12-20 2018-03-07 Affibody AB Engineered albumin binding polypeptide
CN104922682A (zh) * 2014-03-20 2015-09-23 中国科学院大连化学物理研究所 一种胰蛋白酶抑制剂及其应用
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA2949236C (en) 2014-05-15 2023-06-13 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CN113230386B (zh) * 2021-03-07 2022-04-12 合肥天汇孵化科技有限公司 胸腺法新组合物及其用途
US20240366731A1 (en) * 2021-08-12 2024-11-07 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition
KR20230039783A (ko) * 2021-09-07 2023-03-21 ㈜ 디앤디파마텍 거대 생리활성 물질 및 부형제를 포함하는 약학 조성물
WO2025147459A1 (en) * 2024-01-04 2025-07-10 Nano Precision Medical, Inc. Stabilization of peptides and proteins in implantable devices and formulations
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja) 1986-08-20 1988-03-03 株式会社東芝 高速増殖炉の崩壊熱除去システム
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
ES2045276T3 (es) 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
JPH02250823A (ja) 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US6692766B1 (en) * 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
DE69739172D1 (de) * 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
JPH10330287A (ja) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
JP2000050793A (ja) 1998-08-07 2000-02-22 Meiji Milk Prod Co Ltd 人工乳組成物
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
CN1245216C (zh) 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en) * 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko) 2001-03-08 2001-07-25 서종수 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
KR20010069433A (ko) 2001-03-22 2001-07-25 김윤완 노루궁뎅이버섯을 이용한 건강 보조 식품
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
EP1414474A4 (en) 2001-07-18 2005-06-29 Solae Llc PROTEIN BOWMAN BIRK HEMMER CONCENTRATE AND MANUFACTURING METHOD THEREFOR
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2006097793A2 (en) * 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
CN103223160B (zh) * 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
AU2006288703B2 (en) 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) * 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) 2006-06-30 2011-11-16 北京民海生物科技有限公司 一种包含稳定剂的Exendin-4注射剂药物配方
JP2010508262A (ja) 2006-11-01 2010-03-18 プロノヴァ バイオファーマ ノルゲ アーエス 組成物
EP2144618B2 (en) 2007-03-28 2024-11-20 Aker Biomarine Antarctic As Bioeffective krill oil compositions
CA3083198A1 (en) 2008-03-26 2009-10-01 Oramed Ltd. Methods and compositions for oral administration of proteins
EP2300031B1 (en) 2008-05-05 2017-09-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009151125A1 (ja) 2008-06-13 2009-12-17 持田製薬株式会社 肝障害の診断及び治療
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
TWI474835B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
US20090312302A1 (en) 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
UY32177A (es) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
JP5843755B2 (ja) 2009-05-08 2016-01-13 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸
US20120202849A1 (en) 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
EP2519251A4 (en) 2009-12-30 2013-08-28 Solae Llc ISOLATED CLEANED BOWMAN BIRK PROTEASE HEMMER PROTEINS FROM A SOYA PROCESSING STREAM
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
CN102970981A (zh) 2010-07-06 2013-03-13 詹森药业有限公司 糖尿病协同治疗制剂
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (en) 2012-02-01 2024-04-10 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
IL241462A0 (en) * 2015-09-10 2015-11-30 Yeda Res & Dev Heterologous engineering of betalain pigments in plants

Similar Documents

Publication Publication Date Title
CA3083198A1 (en) Methods and compositions for oral administration of proteins
JP2012500254A5 (enExample)
AU2020203101B2 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
Bao et al. Catfish hepcidin gene is expressed in a wide range of tissues and exhibits tissue-specific upregulation after bacterial infection
RU2010146372A (ru) Композиции и способы перорального введения эксенатида
AU2009283821B2 (en) Methods and compositions for oral administration of proteins
FI2571517T4 (fi) Insuliinien pitkävaikutteisia formulaatioita
US20100093636A1 (en) Methods of treating inflammation
JP2015524419A5 (enExample)
KR20170026635A (ko) 장기 재생을 위한 내인성 회장 브레이크 호르몬 경로의 활성화 및 관련 조성물, 치료 방법, 진단법, 및 조절 시스템
JP2016513712A5 (enExample)
JP2011501959A5 (enExample)
WO2011134284A1 (zh) 胰高血糖素样肽-1类似物及其应用
CN103429236A (zh) 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物
HRP20160416T1 (hr) Kapsula za prevenciju kardiovaskularnih bolesti
JP2001526656A (ja) アミリンまたはアミリン・アゴニストを用いる胃炎を予防する方法
Wei et al. Intermittent protein restriction protects islet β cells and improves glucose homeostasis in diabetic mice
AU2017298648A1 (en) 1-methylnicotinamide for the treatment of diseases associated with C-reactive protein
Roa et al. Trefoil factor 3 (TFF3) expression is regulated by insulin and glucose
Wei et al. Mechanisms of sodium-glucose cotransporter 2 inhibitors in heart failure
Lim et al. Butyrate and propionate, short chain fatty acids, attenuate myocardial damages by inhibition of apoptosis in a rat model of ischemia-reperfusion
CN103966243B (zh) 一种dna分子及其在制备糖尿病鼠模型中的应用
Wapnick et al. Changes in glucose tolerance and serum insulin following partial gastrectomy and intestinal resection
Umezawa et al. Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the “right drug” and the “right dose” for dogs
JP2019505572A5 (enExample)